A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

NCT00982657 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class

Stopped Refer to statement in Summary Section/Detailed Description

Conditions

Interventions

Sponsor

Pfizer